167 related articles for article (PubMed ID: 29544740)
1. High neutrophil-to-lymphocyte ratio before starting anti-programmed cell death 1 immunotherapy predicts poor outcome in patients with metastatic melanoma.
Garnier M; Zaragoza J; Bénéton N; Bens G; Meurisse V; Samimi M; Maillard H; Machet L
J Am Acad Dermatol; 2018 Jul; 79(1):165-167.e2. PubMed ID: 29544740
[No Abstract] [Full Text] [Related]
2. Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma.
Perier-Muzet M; Gatt E; Péron J; Falandry C; Amini-Adlé M; Thomas L; Dalle S; Boespflug A
JAMA Dermatol; 2018 Jan; 154(1):82-87. PubMed ID: 29214290
[TBL] [Abstract][Full Text] [Related]
3. Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma.
Chasseuil E; Saint-Jean M; Chasseuil H; Peuvrel L; Quéreux G; Nguyen JM; Gaultier A; Varey E; Khammari A; Dréno B
Acta Derm Venereol; 2018 Apr; 98(4):406-410. PubMed ID: 29327065
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of neutrophil to lymphocyte ratio in advanced melanoma treated with anti-programmed death-1 therapy.
Minowa T; Kato J; Hida T; Horimoto K; Sato S; Sawada M; Uhara H
J Dermatol; 2018 Sep; 45(9):e250-e251. PubMed ID: 29572922
[No Abstract] [Full Text] [Related]
5. Gut microbiome and immunotherapy response.
Burki TK
Lancet Oncol; 2017 Dec; 18(12):e717. PubMed ID: 29129446
[No Abstract] [Full Text] [Related]
6. Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma.
Boussemart L; Johnson A; Schrock AB; Pal SK; Frampton GM; Fabrizio D; Chalmers Z; Lotem M; Gibney G; Russell J; Chmielowski B; Ross JS; Stephens PJ; Miller VA; Ali SM
J Am Acad Dermatol; 2019 Jun; 80(6):1780-1782. PubMed ID: 30576761
[No Abstract] [Full Text] [Related]
7. Melanoma: is immunotherapy of benefit?
Faries MB; Morton DL
Adv Surg; 2003; 37():139-69. PubMed ID: 12953631
[No Abstract] [Full Text] [Related]
8. [Advances in immunotherapy for metastatic melanoma].
Oláh J
Magy Onkol; 2017 Jun; 61(2):132-136. PubMed ID: 28585614
[TBL] [Abstract][Full Text] [Related]
9. Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Fujimura T; Yamamoto Y; Hata H; Tanaka R; Yamaguchi K; Nonomura Y; Hirai I; Furudate S; Okuhira H; Imafuku K; Aoki M; Matsushita S
Br J Dermatol; 2018 Jul; 179(1):213-215. PubMed ID: 29405254
[No Abstract] [Full Text] [Related]
10. A high neutrophil-to-lymphocyte ratio as a potential marker of mortality in patients with Merkel cell carcinoma: A retrospective study.
Zaragoza J; Kervarrec T; Touzé A; Avenel-Audran M; Beneton N; Esteve E; Wierzbicka Hainaut E; Aubin F; Machet L; Samimi M
J Am Acad Dermatol; 2016 Oct; 75(4):712-721.e1. PubMed ID: 27544490
[TBL] [Abstract][Full Text] [Related]
11. Clinical and pathologic factors associated with deep transection of biopsies of invasive melanoma.
Woodcock JL; Eyre ZW; Stoddard GJ; Callis Duffin K; Bowen AR
J Am Acad Dermatol; 2017 Oct; 77(4):766-768. PubMed ID: 28917460
[No Abstract] [Full Text] [Related]
12. The role of nivolumab in melanoma.
Gomes F; Serra-Bellver P; Lorigan P
Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
[TBL] [Abstract][Full Text] [Related]
13. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
15. [Immune checkpoint antibodies increase survival in patients with metastatic melanoma].
Fløe LE; Svane IM; Bastholt L; Schmidt H
Ugeskr Laeger; 2016 Aug; 178(33):. PubMed ID: 27550784
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for the management of advanced melanoma: the next steps.
Zikich D; Schachter J; Besser MJ
Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
[TBL] [Abstract][Full Text] [Related]
17. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
[TBL] [Abstract][Full Text] [Related]
18. Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.
Shah DJ; Dronca RS
Mayo Clin Proc; 2014 Apr; 89(4):504-19. PubMed ID: 24684873
[TBL] [Abstract][Full Text] [Related]
19. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of nivolumab in metastatic melanoma: real-world practice.
Bocquet-Tremoureux S; Scharbarg E; Nguyen JM; Varey E; Quereux G; Saint-Jean M; Peuvrel L; Khammari A; Dreno B
Eur J Dermatol; 2019 Jun; 29(3):315-321. PubMed ID: 31389790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]